Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial

22 May 2023 (11:00 - 11:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Toru Kondo

Nagoya University Graduate School of Medicine, Nagoya (Japan)

4 More presentations in this session

Presentation thumbnail

Efficacy of dapagliflozin according to heart rate in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER

Doctor T. Kondo (Nagoya, JP)

Abstract Slides

Presentation thumbnail

Calcium channel blocker and outcomes in patients with heart failure and mildly reduced or preserved ejection fraction

Doctor S. Matsumoto (Tokyo, JP)

Abstract Slides

Presentation thumbnail

Medium term improvement in left ventricular systolic function following CRT pacemaker implantation indicates additional defibrillator component may not be necessary

Doctor H. Shabbir (Blackburn, GB)

Abstract Slides

Presentation thumbnail

Left bundle branch block cardiomyopathy: an intriguing and defiant entity from diagnosis to treatment

Ms C. Oliveira (Porto, PT)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - treatment 3

The Event

Event poster

Heart Failure 2023

22 May 2023 11:00 CET

You may be interested in

Congress Presentation

Dapagliflozin effect on cardiopulmonary function in HFrEF patients

Congress Presentation

Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure

Congress Presentation

Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources